TRIB TRINITY BIOTECH PLC

Nasdaq trinitybiotech.com


$ 0.98 $ -0.02 (-2.08 %)    

Monday, 27-Oct-2025 15:06:09 EDT
QQQ $ 627.62 $ 0.00 (0 %)
DIA $ 475.16 $ 0.36 (0.08 %)
SPY $ 684.71 $ 1.94 (0.28 %)
TLT $ 91.72 $ 0.41 (0.45 %)
GLD $ 367.23 $ -3.78 (-1.02 %)
$ 1
$ 1.00
$ 0.98 x 800
$ 1.04 x 2,100
$ 0.98 - $ 1.10
$ 0.88 - $ 17.20
59,984
na
17.96M
$ 1.26
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 trinity-biotech-regains-nasdaq-compliance

Trinity Biotech plc (Nasdaq Global Select: TRIB), a commercial-stage biotechnology company focused on human diagnostics and dia...

 trinity-biotech-announces-clinical-trial-results-demonstrating-technical-breakthrough-and-de-risking-commercial-pathway-for-its-next-gen-continuous-glucose-monitoring-technology-called-cgm

Trinity Biotech plc (NASDAQ:TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes managemen...

 mhra-says-received-reports-describing-positive-bias-in-hba1c-results-delivered-by-trinity-biotech-premier-hb9210-hba1c-analyser-says-positive-bias-in-hba1c-results-resulted-in-patients-being-incorrectly-diagnosed-as-pre-diabetic-or-diabetic-trinity-biotech-committed-to-updating-intended-use-statement-in-the-instructions-for-use

https://www.gov.uk/drug-device-alerts/trinity-biotech-premier-hb9210-hba1c-analyser-risk-of-positive-bias-and-updates-to-instru...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION